- Home
- UWMC vs CGEM Comparison
UWMC vs CGEM Comparison
Compare UWMC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- CGEM
- Stock Information
- Founded
- UWMC 1986
- CGEM 2016
- Country
- UWMC United States
- CGEM United States
- Employees
- UWMC N/A
- CGEM N/A
- Industry
- UWMC Finance: Consumer Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- CGEM Health Care
- Exchange
- UWMC Nasdaq
- CGEM Nasdaq
- Market Cap
- UWMC 825.8M
- CGEM 530.0M
- IPO Year
- UWMC N/A
- CGEM 2021
- Fundamental
- Price
- UWMC $4.20
- CGEM $7.45
- Analyst Decision
- UWMC Hold
- CGEM Strong Buy
- Analyst Count
- UWMC 8
- CGEM 6
- Target Price
- UWMC $6.18
- CGEM $28.17
- AVG Volume (30 Days)
- UWMC 7.7M
- CGEM 349.8K
- Earning Date
- UWMC 08-05-2025
- CGEM 08-07-2025
- Dividend Yield
- UWMC 9.54%
- CGEM N/A
- EPS Growth
- UWMC N/A
- CGEM N/A
- EPS
- UWMC N/A
- CGEM N/A
- Revenue
- UWMC $2,486,541,000.00
- CGEM N/A
- Revenue This Year
- UWMC $11.32
- CGEM N/A
- Revenue Next Year
- UWMC $22.84
- CGEM N/A
- P/E Ratio
- UWMC N/A
- CGEM N/A
- Revenue Growth
- UWMC 10.39
- CGEM N/A
- 52 Week Low
- UWMC $3.80
- CGEM $6.85
- 52 Week High
- UWMC $9.74
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- UWMC 49.46
- CGEM 41.65
- Support Level
- UWMC $4.03
- CGEM $7.29
- Resistance Level
- UWMC $4.32
- CGEM $7.94
- Average True Range (ATR)
- UWMC 0.15
- CGEM 0.41
- MACD
- UWMC 0.01
- CGEM -0.00
- Stochastic Oscillator
- UWMC 48.81
- CGEM 21.31
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.